Hong Zhang


Dr. Zhang is a clinical reviewer for anti-tumor and hematological drugs in the Center for Drug Evaluation at the National Medical Products Administration of China. She has participated in the clinical review of investigational new drug applications and new drug applications of many imported and domestic new drugs such as Icotinib, Apatinib, Chidamide, Fruquintinib, Lenvatinib, lenalidomide, biosimilar drugs and immune checkpoint inhibitors, and she has participated in the development of many relevant technical guidelines for the clinical research and development of anti-tumor drugs. 

She earned her Ph.D. from the Health Science Centre at Peking University.